Skip to content

Effect of calcitriol on delayed progression of nonalcoholic fatty liver disease by inhibiting oxidative stress in the liver

Effect of calcitriol on delayed progression of nonalcoholic fatty liver disease by inhibiting oxidative stress in the liver

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012909
Enrollment
Unknown
Registered
2017-10-09
Start date
2015-08-01
Completion date
Unknown
Last updated
2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

Normal Vit D group:without calcitriol
Vit D deficiency group:calcitriol
Vit D insufficient group:calcitriol

Sponsors

Huai'an First Affliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult male and non-pregnant non-lactating women; 2. Aged above 18 years old (include 18 years old), male body weight is at least 50kg, female body weight is at least 45kg, body mass index (BMI) is between 19~26 kg/m2; 3. Blood pressure, pulse rate, breathing condition and electrocardiogram examination are normal; 4. The diagnosis of NAFLD was made for all study participants according to the working definition of NAFLD in China as recommended by the 2010 Revised Guidelines for the Diagnosis and Management of NAFLD published by the Chinese Hepatology Association.

Exclusion criteria

Exclusion criteria: 1. Other chronic liver disease based on histology or pathogen diagnosis such as chronic viral hepatitis, primary biliary cirrhosis, autoimmune liver disease,a1-antitrypsin deficiency, Wilsons disease, hemochromatosis and sclerosing cholangitis; 2. History of recent potentially hepatotoxic drug intake; 3. Weekly alcohol consumption=140g; 4. Renal dysfunction; 5. Hypo- or hyperthyroidism; 6. History of cardiovascular disease; 7. Serum calcium level of =10.5 mg/dL; 8. Current use of drugs known to influence 25(OH)D3 metabolism, including glucocorticoids and calcium/vitamin D supplements; 9. Severe disability, bone fracture; 10. Current infectious condition; 11. The presence of a tumor and severe anemia.

Design outcomes

Primary

MeasureTime frame
25-hydroxyvitamin D3;Serum malondialdehyde;Superoxide Dismutase;Insulin resistance index;Fatty liver index;

Countries

China

Contacts

Public ContactLiu Yuanyuan

Huai'an First Affliated Hospital of Nanjing Medical University

liuyy_suda@163.com+86 18360906118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026